Lymphoma

The ESPN sportscaster Dick Vitale was diagnosed with lymphoma, after receiving a melanoma diagnosis earlier this year.

Engineered cell technology is an example of ingenuity that brings together cutting-edge laboratory science and clinical trials to address aggressive cancers.

Patients with blood cancers may respond differently to doses of the COVID-19 vaccines based on the treatment they’re receiving, for example.

Natural killer cell therapy is making strides in blood cancer research, but there’s still much more to learn.

Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.

From Blink-182 bandmember Mark Hoppus’s cancer update to Olympian Elizabeth Beisel’s swim for cancer, here’s what’s happening in the cancer landscape this week.

While the recent FDA approval of Jakafi offers another effective option for patients with chronic GVHD, one expert urges that more work needs to be done to prevent and/or reverse the condition.

Certain races/ethnicities and ages may have worse outcomes in Hodgkin lymphoma regardless of variation in upfront chemotherapy.

The tome also reflects on his own diagnosis of cancer and how it influenced his practice.

The FDA has granted approval to Jakafi (ruxolitinib) for the treatment of chronic graft-versus-host disease (GVHD).

Patients with blood cancer who underwent stem cell transplant and developed chronic graft-versus-host disease have more treatment options than ever before. But the formula for planning older and newer therapies has not yet been established.

From Jeff Bridges achieving remission from cancer to a cancer survivor who became a runway model, here’s what’s happening in the cancer landscape this week.

Patients with relapsed/refractory, pretreated marginal zone lymphoma are now eligible for treatment with Brukinsa.

The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

A recent webinar from the Lymphoma Research Foundation gave important advice for caregivers, including the importance of taking care of oneself.

Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

Researchers are evaluating the safety and efficacy of zandelisib, an investigational cancer therapy, for the treatment of patients with marginal zone lymphoma and follicular lymphoma who have received at least two prior therapies.

Adolescent and young adult patients are more represented than previously expected in clinical trials. However, their outcomes still lag behind the younger and older populations.

Blood cancer survivors are living longer than ever, making safe pain management an important concern.

In his new memoir, a patient with central nervous system lymphoma emphasizes the importance of a positive mindset and a strong support system.

Nina Luker, a healthy 25 year old, felt invincible. But she says that "naïve perspective was disrupted in a matter of hours."

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

From a 90-year-old man’s 3,600-mile walk to raise money for children with cancer to the death of KISS and Cinderella keyboardist Gary Corbett, here’s what’s happening in the cancer landscape this week.

The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.

One expert tells patients to ‘hang tight’ as immunotherapy options are getting better each year.

These findings, according to one of the study’s authors, demonstrate that Yescarta addresses an important unmet medical need for patients with relapsed/refractory follicular lymphoma.

Treatment with the combination of Polivy, rituximab and lenalidomide safely conferred responses in patients with relapsed/refractory diffuse large B-cell lymphoma, with most patients still in remission at the study’s cutoff date.

Combination therapy with Aliqopa and rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.